0001788028
false
0001788028
2023-11-09
2023-11-09
0001788028
JSPR:VotingCommonStockParValue0.0001PerShareMember
2023-11-09
2023-11-09
0001788028
JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member
2023-11-09
2023-11-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 9, 2023
JASPER
THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39138 |
|
84-2984849 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
2200 Bridge Pkwy Suite #102
Redwood City, CA |
|
94065 |
(Address of principal executive offices) |
|
(Zip Code) |
(650) 549-1400
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Voting Common Stock, par value $0.0001 per share |
|
JSPR |
|
The Nasdaq Stock Market LLC |
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 |
|
JSPRW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations
and Financial Condition.
On November 9, 2023, Jasper Therapeutics,
Inc. issued a press release reporting its financial results for the quarter ended September 30, 2023 and providing a business update.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instructions
B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished
under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section,
and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
JASPER THERAPEUTICS, INC. |
|
|
|
Date: November 9, 2023 |
By: |
/s/ Herb Cross |
|
|
Name: Herb Cross |
|
|
Title: Chief Financial Officer |
Exhibit 99.1
Jasper Therapeutics Reports Third Quarter 2023
Financial Results and Provides Business Update
REDWOOD CITY, Calif., November 9, 2023
– Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody
therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria
(CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens,
today announced results for the fiscal quarter ended September 30, 2023, and provided a business update.
“The third quarter was a highly productive
period for Jasper, punctuated in October by the announcement of FDA clearance of our investigational new drug (IND) application for a
Phase 1b/2a clinical study evaluating subcutaneous briquilimab in the treatment of CSU,” said Ronald Martell, President and Chief
Executive Officer of Jasper. “This is a significant milestone for the Company, representing our first step in the clinical development
of briquilimab in mast cell driven diseases, and we look forward to dosing the first patient in our CSU study later this year. We also
continued to strengthen our board of directors and senior leadership team with multiple key additions during the period. With a strong
balance sheet, experienced team and robust development plans, we believe we are well-positioned to advance our briquilimab programs across
a range of indications going forward.”
Recent Developments and Highlights
| ● | Jasper
obtained IND clearance for initiation of a Phase 1b/2a study of subcutaneous briquilimab in CSU. The study is a dose escalation trial
evaluating repeat doses of subcutaneous briquilimab in adult CSU patients who remain symptomatic after treatment with, or who cannot
tolerate, omalizumab, and is expected to enroll approximately 40 patients across 6 cohorts at sites in the US and EU. Jasper expects
to enroll the first patient by the end of 2023 and to report interim data on multiple cohorts by mid-2024. |
| ● | Jasper hosted a key opinion leader webinar on
the potential of briquilimab as a therapeutic in chronic urticaria, as well as the current treatment landscape and unmet medical need
for patients suffering from CSU. A replay of the webinar is available at this link. |
| ● | New positive data from a Stanford
sponsored Phase 1/2 study of briquilimab conditioning in patients with Fanconi Anemia was presented at the 2023 Fanconi Anemia Research
Fund Scientific Symposium. Briquilimab was well-tolerated without any complications and all three Fanconi Anemia patients treated
in the study achieved full donor engraftment as well as full blood count recovery. Stanford has expanded the study into Phase 2a. |
| ● | Jasper continued to strengthen the organization
with the appointment of Thomas Wiggans as Chairperson of the Board of Directors and Herb Cross as Chief Financial Officer. |
Q3 2023 Financial Results
| ● | Cash and cash equivalents as of September 30,
2023, totaled $103.9 million. |
| ● | Research and development expenses for the three
months ended September 30, 2023, were $14.8 million, including stock-based compensation expenses of $0.4 million. |
| ● | General and administrative expenses for the three
months ended September 30, 2023, were $4.5 million, including stock-based compensation expenses of $1.0 million. |
| ● | Jasper reported a net loss of $17.5 million,
or basic and diluted net loss per share attributable to common stockholders of $0.16, for the three months ended September 30, 2023. |
About Briquilimab
Briquilimab (formerly JSP191) is a targeted aglycosylated
monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting
signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via
apoptosis which removes the underlying source of the inflammatory response in mast cell driven disease such as chronic urticaria. Jasper
intends to start clinical studies of briquilimab as a primary treatment in Chronic Spontaneous Urticaria as well as in Chronic Inducible
Urticaria. Briquilimab is also currently in clinical studies as a treatment for patients with Low to Intermediate Risk myelodysplastic
syndromes (MDS) and as a conditioning agent for cell and gene therapies for rare diseases. To date, briquilimab has a demonstrated efficacy
and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in severe
combined immunodeficiency (SCID), acute myeloid leukemia (AML), MDS, Fanconi anemia (FA), and sickle cell disease (SCD).
About Jasper
Jasper is a clinical-stage biotechnology company
developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as
chronic urticaria and lower to intermediate risk MDS and as a conditioning agent for stem cell transplants for rare diseases such as SCD,
FA and SCID. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers,
with clinical outcomes as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.
Forward-Looking Statements
Certain statements included in this press release
that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,”
“may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
“expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,”
“seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends
or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding
briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU and LR-MDS, as
well as novel stem cell transplant conditioning regimens; Jasper’s expectations regarding its Phase 1b/2a study of subcutaneous
briquilimab in CSU, including the expected timing of dosing of the first patient, the number of patients to be dosed, the cohorts, the
site locations, expected enrollment and expected timing for reporting interim data; and Jasper’s expectations regarding the advancement
of its briquilimab programs across a range of indications. These statements are based on various assumptions, whether or not identified
in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking
statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as,
a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond
the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic,
political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical
development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm
any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to
successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the
risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness
to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business;
the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will
fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply
chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient
intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and
other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form
10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s
assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While
Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent
to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
John Mullaly (investors)
LifeSci Advisors
617-429-3548
jmullaly@lifesciadvisors.com
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertherapeutics.com
Lauren Barbiero (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com
--- tables
to follow---
JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS
(in thousands, except share and per share
data)
(unaudited)
| |
Three Months Ended
September 30, | | |
Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Operating expenses | |
| | |
| | |
| | |
| |
Research and development(1) | |
$ | 14,848 | | |
$ | 9,022 | | |
$ | 37,950 | | |
$ | 25,345 | |
General and administrative(1) | |
| 4,514 | | |
| 3,686 | | |
| 13,186 | | |
| 12,104 | |
Total operating expenses | |
| 19,362 | | |
| 12,708 | | |
| 51,136 | | |
| 37,449 | |
Loss from operations | |
| (19,362 | ) | |
| (12,708 | ) | |
| (51,136 | ) | |
| (37,449 | ) |
Interest income | |
| 1,433 | | |
| 259 | | |
| 3,965 | | |
| 353 | |
Change in fair value of earnout liability | |
| 334 | | |
| 422 | | |
| (10 | ) | |
| 5,640 | |
Change in fair value of common stock warrant liability | |
| — | | |
| 155 | | |
| (575 | ) | |
| 7,050 | |
Other income (expense), net | |
| 51 | | |
| 9 | | |
| (128 | ) | |
| (68 | ) |
Total other income, net | |
| 1,818 | | |
| 845 | | |
| 3,252 | | |
| 12,975 | |
Net loss and comprehensive loss | |
$ | (17,544 | ) | |
$ | (11,863 | ) | |
$ | (47,884 | ) | |
$ | (24,474 | ) |
Net loss per share attributable to common stockholders, basic and diluted | |
$ | (0.16 | ) | |
$ | (0.32 | ) | |
$ | (0.47 | ) | |
$ | (0.67 | ) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | |
| 109,720,741 | | |
| 36,565,650 | | |
| 102,351,140 | | |
| 36,425,000 | |
(1) Amounts include non-cash stock based compensation expense as follows (in thousands):
| |
Three Months Ended
September 30, | | |
Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Research and development | |
$ | 381 | | |
$ | 169 | | |
$ | 1,340 | | |
$ | 976 | |
General and administrative | |
| 1,014 | | |
| 475 | | |
| 2,713 | | |
| 1,511 | |
Total | |
$ | 1,395 | | |
$ | 644 | | |
$ | 4,053 | | |
$ | 2,487 | |
JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
| |
September 30,
2023 | | |
December 31,
2022 | |
Assets | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 103,867 | | |
$ | 38,250 | |
Other receivables | |
| — | | |
| 663 | |
Prepaid expenses and other current assets | |
| 1,351 | | |
| 2,818 | |
Total current assets | |
| 105,218 | | |
| 41,731 | |
Property and equipment, net | |
| 2,780 | | |
| 3,568 | |
Operating lease right-of-use assets | |
| 1,579 | | |
| 1,886 | |
Restricted cash | |
| 417 | | |
| 417 | |
Other non-current assets | |
| 411 | | |
| 759 | |
Total assets | |
$ | 110,405 | | |
$ | 48,361 | |
Liabilities and Stockholders’ Equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 3,256 | | |
$ | 1,768 | |
Current portion of operating lease liabilities | |
| 945 | | |
| 865 | |
Current portion of earnout liability | |
| 28 | | |
| — | |
Accrued expenses and other current liabilities | |
| 7,677 | | |
| 4,432 | |
Total current liabilities | |
| 11,906 | | |
| 7,065 | |
Non-current portion of operating lease liabilities | |
| 2,069 | | |
| 2,786 | |
Common stock warrant liability | |
| — | | |
| 150 | |
Non-current portion of earnout liability | |
| — | | |
| 18 | |
Other non-current liabilities | |
| 2,297 | | |
| 2,353 | |
Total liabilities | |
| 16,272 | | |
| 12,372 | |
Commitments and
contingencies | |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Preferred stock | |
| — | | |
| — | |
Common stock | |
| 11 | | |
| 4 | |
Additional paid-in capital | |
| 247,141 | | |
| 141,120 | |
Accumulated deficit | |
| (153,019 | ) | |
| (105,135 | ) |
Total stockholders’ equity | |
| 94,133 | | |
| 35,989 | |
Total liabilities and stockholders’ equity | |
$ | 110,405 | | |
$ | 48,361 | |
v3.23.3
Cover
|
Nov. 09, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 09, 2023
|
Entity File Number |
001-39138
|
Entity Registrant Name |
JASPER
THERAPEUTICS, INC.
|
Entity Central Index Key |
0001788028
|
Entity Tax Identification Number |
84-2984849
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2200 Bridge Pkwy Suite #102
|
Entity Address, City or Town |
Redwood City
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94065
|
City Area Code |
650
|
Local Phone Number |
549-1400
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Voting Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Voting Common Stock, par value $0.0001 per share
|
Trading Symbol |
JSPR
|
Security Exchange Name |
NASDAQ
|
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 |
|
Title of 12(b) Security |
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50
|
Trading Symbol |
JSPRW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=JSPR_VotingCommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=JSPR_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From May 2024 to Jun 2024
Jasper Therapeutics (NASDAQ:JSPR)
Historical Stock Chart
From Jun 2023 to Jun 2024